AR and prostate carcinoma: Treatment with androgen receptor antagonists or interfering with the synthesis of androgens remains the standard therapy for patients with advanced or metastatic forms of prostate cancer, as the prostate epithelium regresses after removal of androgens or blockade of the androgen receptor (AR) [3,4,5].